These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 1617962)

  • 21. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
    Paoletti AM; Orrù M; Floris S; Mannias M; Vacca AM; Ajossa S; Guerriero S; Melis GB
    Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
    Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
    Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbohydrate metabolism of Indian women taking steroid contraceptives.
    Barsivala VM; Virkar K; Kulkarni RD
    Fertil Steril; 1976 Jan; 27(1):87-91. PubMed ID: 1245247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
    Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
    Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
    Spellacy WN
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gestodene-containing contraceptives.
    Kuhl H; Jung-Hoffmann C; Wiegratz I
    Clin Obstet Gynecol; 1995 Dec; 38(4):829-40. PubMed ID: 8616979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open prospective study on the effects on carbohydrate metabolism of an oral monophasic contraceptive containing gestodene (WL-70).
    Trossarelli GF; Bordon R; Gennarelli GL; Carta Q
    Contraception; 1991 May; 43(5):423-33. PubMed ID: 1914457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of desogestrel on carbohydrate metabolism.
    Shoupe D
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene.
    Renier M; Buytaert P
    Contraception; 1991 May; 43(5):413-21. PubMed ID: 1914456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
    Spellacy WN; Ellingson AB; Tsibris JC
    Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbohydrate metabolic studies during twelve months of treatment with a low-dose combination oral contraceptive.
    Ramamoorthy R; Saraswathi TP; Kanaka TS
    Contraception; 1989 Nov; 40(5):563-9. PubMed ID: 2692964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasound evaluation of ovarian activity under oral contraceptives.
    Hoogland HJ; Skouby SO
    Contraception; 1993 Jun; 47(6):583-90. PubMed ID: 8334892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
    Weber-Diehl F; Lehnert J; Lachnit U
    Contraception; 1993 Oct; 48(4):291-301. PubMed ID: 8222658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.